Nucleic acid molecule capable of binding to c-Met and use thereof
View Patent ↗The present invention provides a nucleic acid molecule capable of binding to c-Met as a substance that can be used for clarification of the pathogenic mechanism of diseases caused by c-Met, diagnosis and treatment of the diseases, and the like, and also the use thereof. The c-Met binding nucleic acid molecule of the present invention is any one of the following nucleic acid molecules (A1), (A2), (B1), and (B2). (A1) a nucleic acid molecule including the base sequence of any one of SEQ ID NOs: 1 to 38 (A2) a nucleic acid molecule that is capable of binding to c-Met and includes a base sequence obtained by substitution, deletion, addition, and/or insertion of one or more bases in the base sequence of any one of SEQ ID NOs: 1 to 38 (B1) a nucleic acid molecule including the base sequence of any one of SEQ ID NOs: 39 to 76 (B2) a nucleic acid molecule that is capable of binding to c-Met and includes a base sequence obtained by substitution, deletion, addition, and/or insertion of one or more bases in the base sequence of any one of SEQ ID NOs: 39 to 76.
1. A nucleic acid aptamer molecule that binds to c-Met, wherein said aptamer molecule consists of the sequence of SEQ ID NO: 76.
2. The aptamer molecule according to claim 1 , wherein the aptamer molecule contains at least one modified nucleotide.
3. The aptamer molecule according to claim 2 , wherein said at least one modified nucleotide is selected from the group consisting of a methylated nucleotide, a fluorinated nucleotide, an aminated nucleotide, and a thiated nucleotide.
4. The aptamer molecule according to claim 2 , wherein said at least one modified nucleotide is a modified cytosine or modified uracil.
5. The aptamer molecule according to claim 2 , wherein said at least one modified nucleotide is a nucleotide with a modified ribose residue.
6. A neutralizer comprising:
the aptamer molecule according to claim 1 ,
wherein the neutralizer neutralizes the function of a c-Met protein by binding of the aptamer molecule to the c-Met protein.
7. An inhibitor comprising:
the aptamer molecule according to claim 1 ,
wherein the inhibitor inhibits the function of a c-Met protein by binding of the aptamer molecule to the c-Met protein.
8. A pharmaceutical agent comprising:
the aptamer molecule according to claim 1 .
9. The pharmaceutical agent according to claim 8 , wherein the pharmaceutical agent is selected from the group consisting of anticancer agents, antiinflammatory agents, antihepatopathy agents, and anti-amyotrophic lateral sclerosis agents.
10. A composition comprising:
the aptamer molecule according to claim 1 .
11. The composition according to claim 10 , further comprising a carrier.
12. A c-Met detection reagent for detecting a c-Met protein, wherein the c-Met detection reagent comprises the aptamer molecule according to claim 1 .